Blank Rome LLP will convene its 10th Annual State of the Cannabis Industry Conference on Monday, October 26, from 8:30 a.m. to 6 p.m. ET at the Omni Boston Hotel at the Seaport, with a live-stream option for those who can't make the trip. The gathering pulls together operators, regulators, lenders, investors, and legal counsel to work through the operational and policy questions still unresolved a decade into the firm's coverage of the sector - which, fair enough, is longer than most law firm conference series manage to stay relevant.
A Hall of Fame Arrives, and a Regulator Takes Questions
To mark the milestone, Blank Rome is launching a Cannabis Industry Hall of Fame, with inaugural honors going to Boris Jordan of Curaleaf, George Archos of Verano, and Charlie Bachtell of Cresco Labs - three executives whose companies helped define vertical integration and multi-state operation as the industry's dominant business model. The three will sit for a panel with Frank Segall examining how the market got here and where consolidation, regulation, and capital constraints might take it next.
Separately, Massachusetts Cannabis Control Commission Chair Christopher Harding will join Segall for a fireside conversation on the Commission's priorities. For operators licensed in the state, this is the session worth clearing a calendar for - regulators rarely speak this directly about enforcement posture, license review timelines, or where compliance scrutiny is headed next.
Rescheduling, DEA Registration, and the Compliance Fallout
One panel, moderated by Blank Rome partner Vijay S. Choksi, digs into the shift from Schedule I to Schedule III and what that actually means on the ground. Rescheduling sounds like a clean policy fix on paper, but in practice it raises thorny questions: Does DEA registration apply to existing state-licensed cultivators and manufacturers? How does a Schedule III classification interact with state seed-to-sale tracking systems like METRC, or with existing lab testing and COA requirements? The panel - featuring voices from the American Trade Association for Cannabis and Hemp, CBIZ, the Association of Cannabinoid Specialists, and CitraChem - will try to separate what's settled from what's still speculation. One thing operators are watching closely: whether rescheduling finally eases the 280E tax burden that has squeezed margins across the industry since recreational markets began opening.
Capital, Payments, and the Distressed Deal Market
Three sessions address the financial mechanics keeping operators up at night. A capital markets panel, led by Sean P. Coyle, brings together lenders including Needham Bank, Altmore Capital, Chicago Atlantic, Seaport Global Securities, Millstreet Capital Management, and East West Bank to discuss credit risk, refinancing pressure, and where investor appetite still exists in a sector that remains largely cut off from conventional banking.
A second panel, moderated by Lauren Medeiros Forster, turns to payments, point-of-sale infrastructure, and data analytics - the back-office plumbing that determines whether a dispensary can reconcile its books, manage SKU-level inventory, or offer anything close to cashless convenience at the counter. Panelists from Reklaim Credit Solutions, Shield Compliance, and Sweed POS will speak to how far the technology has actually come since cash-only transactions were the industry norm.
A third, on distressed M&A and restructuring, moderated by Scott H. Moskol, addresses the less glamorous reality of a maturing market: consolidation, workouts, and acquisitions driven by continued price compression and oversupply in several state markets. Speakers from Opus Consulting, SSC Advisors, Vireo Growth, Ascend Wellness Holdings, and HUB International will walk through how lenders and acquirors are underwriting risk in deals that, a few years ago, might not have penciled out at all.
Why This Matters Beyond the Conference Room
Taken together, the agenda reads like a snapshot of an industry caught between regulatory limbo and operational maturity. Dispensary operators still contend with state-by-state compliance regimes, inconsistent banking access, and tax treatment that punishes profitability. Investors and lenders, meanwhile, are recalibrating what a cannabis balance sheet should look like heading into a possible federal policy shift. None of these questions resolve cleanly - but a room full of regulators, operators, and capital providers comparing notes is, at minimum, a useful gauge of where the pressure points actually sit.
